Zanubrutinib combined with rituximab and lenalidomide (ZR2) produced high remission rates and durable survival in adults aged 75 years and older with newly diagnosed diffuse large B-cell lymphoma (DLBCL), according to phase 2…
Author: admin
-

No. 15 Spartan Women’s Basketball Erases 16-Point Deficit To Defeat Ducks, 85-81 Sunday
EUGENE, Oregon — Despite trailing by as many as 16 points in the first half, the No. 15 Michigan State women’s basketball team rallied for an 85-81 win at Oregon on Sunday at Matthew Knight Arena.The Spartans have now won eight-straight games to…
Continue Reading
-
Bannu CTD kills two terrorists in IBO – Dawn
- Bannu CTD kills two terrorists in IBO Dawn
- Terror attack on police check post foiled in Bannu The Nation (Pakistan )
- Pakistan: Police personnel injured after attack on vehicle in Khyber Pakhtunkhwa IANS LIVE
- Two terrorists involved in police…
Continue Reading
-

CBA Emergency Assistance for natural disaster affected areas in Queensland
Commonwealth Bank will provide its Emergency Assistance to customers and businesses in areas affected by significant weather events in Queensland.
Retail Banking Services Group Executive, Angus Sullivan, stated “We are continuing to assess the impacts of flooding and severe weather across parts of Queensland. Our focus is on supporting our customers, communities and employees, with a range of measures in place to help customers navigate their recovery and access support if needed. We also recognise and thank emergency services personnel and volunteers for their work to assist and support impacted communities.”
CBA understands each customer will have different needs and we encourage them to discuss their individual circumstances by either contacting the bank in the CommBank app or phoning 1800 314 695. Business customers can also call 1800 314 695 or speak with their dedicated CommBank relationship manager.
For more information on the support we’re providing to impacted communities, visit: commbank.com.au/support/emergency-assistance.
CBA Emergency Assistance includes a range of options for eligible customers, including:
- Customised payment arrangements for home loans, business loans, personal loans and credit cards.
- Waiving fees and charges, including waiving fees for temporary and damaged merchant EFTPOS terminals, as well as support with merchant terminal rental fees.
- Temporary overdrafts, additional loans or emergency credit limit increases (subject to credit approval).
- Waiving fees and notice periods for early access to Term Deposits (including Farm Management Term Deposits).
- Temporary accommodation may be available for customers who have taken out Home Insurance provided by Hollard, distributed by CommBank, subject to making a claim and policy terms and conditions.
- Helping direct claims enquiries for customers seeking support through their Home Insurance provided by Hollard, distributed by CommBank.
To access this support, customers should contact the bank through the CommBank app. Alternatively, they can call 1800 314 695. Branch availability and further information about CBA’s Emergency Assistance is available online at commbank.com.au/support/emergency-assistance.
For emergency help call the State Emergency Service on 132 500 or visit your State Emergency Service Website
In a life-threatening emergency call 000 (triple zero).
Be alert to scams
During this time customers should also remain vigilant and be extra cautious of unexpected calls or messages claiming to be from well-known organisations including banks, telecommunications companies and government agencies.
CommBank will never send customers links in text messages directing them to sites that ask for passwords, and customers should never click on any of these they receive.
If customers receive an unexpected call claiming to be from CommBank, they should ask the caller to verify the legitimacy of the call by using CallerCheck which triggers a security message in the CommBank App.
How customers can better protect themselves from scams:
- Stop: Does a call, email or text seem off? The best thing to do is stop. Take a breath. Real organisations won’t put you under pressure to act instantly.
- Check: Ask someone you trust or contact the organisation the message claims to be from.
- Reject: If you’re unsure, hang up on the caller, delete the email, block the phone number.
- Change your passwords.
Continue Reading
-

Annual Solar Eclipse 2026: When, Where and How to watch this space event – Moneycontrol
- Annual Solar Eclipse 2026: When, Where and How to watch this space event Moneycontrol
- The Best Skywatching and Stargazing Events of 2026 Scientific American
- 2026 begins a golden age of solar eclipses: How to see 3 total solar eclipses and 3 ‘ring…
Continue Reading
-

Timothée Chalamet, Paul Thomas Anderson take honours at Gloden Globes | Entertainment News
DEVELOPING STORYDEVELOPING STORY,
Chalamet picks up best actor award for his role in sport comedy-drama Marty Supreme.
Published On 12 Jan 2026
Hollywood actor Timothée Chalamet has nabbed…
Continue Reading
-

Australia’s new mandatory merger control regime: Notification waivers
From 1 January 2026, Australia will become a mandatory and suspensory merger control regime. Businesses must notify the Australian Competition and Consumer Commission (ACCC) of acquisitions that meet specified thresholds and cannot complete these acquisitions without approval. To streamline approval for low-risk deals, a waiver notification process has been established.
What is a notification waiver?
A notification waiver is an ACCC decision that an acquisition does not need to be reported, even if it meets the notification thresholds established under the Competition and Consumer Act 2010 (Cth) (CCA) and the Competition and Consumer (Notification of Acquisitions) Determination (Determination). This process provides a quick and inexpensive way for acquisitions unlikely to affect competition or harm consumers to proceed without being in breach of notification obligations.
Importantly, the waiver process is not an alternative for all transactions, particularly those that raise competition issues. It should also not be considered a first step in the clearance process where there are overlaps that will require more detailed consideration. Waivers are appropriate for straightforward acquisitions that can be assessed quickly based on upfront information, without further investigation or third-party consultation.
When might a waiver be appropriate?
The ACCC has indicated that a waiver may be considered where there is:
- no or minimal competitive overlap, combined with very low market share (e.g., ~5%) and many alternative suppliers
- no vertical or conglomerate concerns, or both parties have very low market shares
- No complex scenarios, such as:
- potential loss of future competition (nascent competitors or likely entrants)
- high market concentration or vigorous competitor status
- failing firm situations
- complicated multi-segment markets
- no risk of consumer harm
- no need for third-party inquiries
- asset acquisitions where assets are not scarce and rivals can easily obtain similar assets
Waiver information requirements
The information requirements for a waiver application are still substantial and include details of:
- the Parties to the acquisition and the goods, services and industries involved
- acquisition and transaction information, including type of acquisition (horizontal, vertical, conglomerate, business input), commercial rationale, consideration, transaction value, related filings in other jurisdictions
- the threshold met and any exemptions
- the effect on competition, including for each relevant good/service with horizontal or vertical overlap, description and geographic supply areas, key suppliers in Australia, relevant market definitions and reasons, market share estimates for each party and key competitors (based on revenue for the last 12 months and including any underlying data in machine-readable format).
Final or most recent transaction documents, a list of related agreements, and a declaration by an authorised person confirming the accuracy and completeness of the application must also be included for the application to be valid.
Process and timelines
Waiver applications will be assessed from 12 January 2026 with an application fee of AUD$8,300 per acquisition. Applications are submitted online and the process is public with determinations published on the acquisitions register.
The ACCC is required to make its decision within 25 business days. If a decision is not made, the ACCC must not grant the waiver. Where the parties meet the notification thresholds, the principal party will be required to re-notify the transaction under a Phase 1 review.
Importantly, waivers do not provide statutory protection, cannot cure stale acquisitions (previously notified but not completed within 12 months) and are not available for transactions outside the definition of “acquisition” under the CCA.
Key takeaways
Whether the new merger control regime applies should be assessed early. Taking the correct approach will be critical in meeting deal timelines. If thresholds are met, an assessment will need to be made as to whether the transaction is truly low risk from a competition law perspective to determine if a waiver is appropriate.
Information is still required to be robust and insufficient information may lead to refusal. It will be important to plan for contingencies in deal completion timing and assess the extent to which statutory notification is required by the parties as conditions to completion.
The waiver process will assist with streamlining truly no risk transactions. Any acquisition that raises any element of competition assessment will need to be considered carefully to ensure that a waiver is the most appropriate avenue under the mandatory merger control regime.
White & Case means the international legal practice comprising White & Case LLP, a New York State registered limited liability partnership, White & Case LLP, a limited liability partnership incorporated under English law and all other affiliated partnerships, companies and entities.
This article is prepared for the general information of interested persons. It is not, and does not attempt to be, comprehensive in nature. Due to the general nature of its content, it should not be regarded as legal advice.
© 2026 White & Case LLP
Continue Reading
-
Australian team develops targeted therapy for rare blood cancer-Xinhua
CANBERRA, Jan. 12 (Xinhua) — Researchers in Australia have developed a new targeted therapeutic approach that could improve treatment for myelofibrosis, a rare and serious form of blood cancer.
Published in the journal Blood, the research…
Continue Reading
-
Clover Initiates Phase 2 Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates
— Phase 2 Initiation Strengthens Global First-in-Class Potential for Clover’s Protein-Based RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates —
SHANGHAI, Jan. 12, 2026 /PRNewswire/ — Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced that enrollment of the first participants has been completed in a Phase 2 clinical trial in Australia evaluating SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) protein-based vaccine candidates based on prefusion-stabilized F (PreF)-Trimer subunit vaccine antigens utilizing Clover’s validated Trimer-Tag vaccine technology platform.
“The initiation of this Phase 2 trial for our respiratory combination vaccine candidates SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) further strengthens our global first-in-class potential,” said Joshua Liang, Chief Executive Officer & Board Director of Clover. “This milestone builds upon our recent Phase 1 data indicating potential best-in-class RSV+hMPV±PIV3 combination vaccines with the potential ability to re-vaccinate individuals previously receiving approved RSV vaccines to restore and broaden protection, addressing multiple significant unmet needs globally.”
The ongoing Phase 2 trial for Clover’s combination vaccine candidates is a randomized, observer-blinded, multi-center study enrolling up to 420 older adults (60-85 years) in Australia, and the participants will be randomized to receive either SCB-1022 (RSV + hMPV), SCB-1033 (RSV + hMPV + PIV3) or placebo. The study will assess safety, reactogenicity and immunogenicity.
About Clover
Clover Biopharmaceuticals is a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world. With integrated research and development, manufacturing and commercial capabilities as well as strong partnerships with organizations globally, Clover has a diverse pipeline of candidates that have the potential to meaningfully reduce the burden of vaccine-preventable diseases—and to make more diseases preventable.
Clover Forward-looking Statements
This press release contains certain forward-looking statements and information relating to us and our subsidiaries that are based on the beliefs of our management as well as assumptions made by and information currently available to our management. When used, the words “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “going forward,” “intend,” “may,” “might,” “ought to,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “will,” “would” and the negative of these words and other similar expressions, as they relate to us or our management, are intended to identify forward-looking statements. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. We give no assurance that these expectations and assumptions will prove to have been correct. Because forward-looking statements relate to the future, they are participant to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. We caution you therefore against placing undue reliance on any of these forward-looking statements. Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time.
SOURCE Clover Biopharma

Continue Reading
-

Kolkata to Karachi? Pakistan jumps into India-Bangladesh T20 World Cup venue fight, Mohsin Naqvi offers to host matches
The Pakistan Cricket Board (PCB) has stepped into the India-Bangladesh venue issue for the 2026 T20 World Cup, offering its grounds as an alternative. The move comes after Bangladesh refused to travel to India for the tournament, pushing the…Continue Reading
